Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by University of Turin, Italy.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT00796198
First received: November 21, 2008
Last updated: November 24, 2008
Last verified: November 2008

November 21, 2008
November 24, 2008
December 2008
June 2009   (final data collection date for primary outcome measure)
To evaluate the effects of Cosopt on ODPP in patients not adequately controlled with latanoprost alone [ Time Frame: baseline, at 1 and 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00796198 on ClinicalTrials.gov Archive Site
To evaluate the effects of Cosopt on IOP lowering in patients not adequately controlled with latanoprost alone. [ Time Frame: baseline, at 1 and 3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure
A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy

Hypothesis: Studies suggest that patients with low diastolic velocity and high resistivity index in the ophthalmic artery had more progressive visual fields, the investigators hypothesize therefore that addition of Cosopt to Latanoprost could improve ocular diastolic perfusion pressure (ODPP).

Objective: To evaluate the effects of Cosopt on ODPP in patients not adequately controlled with latanoprost alone.

Fifty patients with primary open angle glaucoma (POAG) treated with Xalatan for whom the monotherapy was not sufficient to achieve the target IOP, will be included in the study. Non responders were defined when IOP was > 20 mmHg or if the IOP reduction was less than 25% from the baseline IOP. Patients will be classified as having POAG when they had a typical glaucomatous visual field and/or a typical abnormal optic nerve head, open angle at gonioscopy, IOP > 21 mmHg with no treatment and no clinically apparent secondary cause for their glaucoma (EGS guidelines).

Visual fields will be assessed by an Humphrey Field Analyzer 750 (HFA, Humphrey, Inc, CA, USA), 24-2 SITA (Swedish Interactive Threshold Algorithm) standard. A glaucomatous visual field defect was defined as: 1) three adjacent points depressed by 5 dB, with one of the points depressed by at least 10 dB; 2) two adjacent points depressed by 10 dB; or 3) a 10 dB difference across the nasal horizontal meridian in two adjacent points. None of the points could be edge points unless immediately above or below the nasal horizontal meridian. In addition, visual field testing was considered reliable only when false-negative responses were less than 30% and fixation losses were less than 20% on HFA.

The abnormal optic nerve head classification was based on the presence of an optic rim notch or of diffuse / generalized loss of optic rim tissue, vertical cup/disc diameter ratio asymmetry unexplained by side differences in optic disc size, disc haemorrhage.

In each centre, patient's recruitment will start as soon as the ethical committee will approve the protocol. Each sites will recruit 10 patients (5 + 5).

Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25), while when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25).

(EGS guidelines: Target pressure is a subjective value that none is able to assess (until now!). Efficacy of a drug: when the medication can decrease IOP as described in the phase three of their clinical trial. Not sufficient: when the medication is effective but is not able to reach the target IOP.)

Each patient will be submitted to three different visits:

  • Baseline visit: Systemic Pressure, IOP, VF, HRF, Visual Acuity, ophthalmic examination with corneal central thickness (CCT)
  • Visit at 1 month: Systemic Pressure , IOP, Visual Acuity, ophthalmic examination
  • Visit at 3 months: Systemic Pressure, IOP , HRF, Visual Acuity, ophthalmic examination (+ CCT) ODPP will be calculated by: "systemic diastolic pressure - IOP" at each session.
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Glaucoma
  • Drug: Xalatan+Cosopt
    Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
  • Drug: Xalatan
    Xalatan ophthalmic solution one drop at 10pm
  • Active Comparator: Xalatan+Cosopt
    Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
    Interventions:
    • Drug: Xalatan+Cosopt
    • Drug: Xalatan
  • Active Comparator: Xalatan
    when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
    Intervention: Drug: Xalatan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
50
July 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • POAG patients with a pattern deviation score (or its equivalent) ranging from 2.5 dB to 6.0 dB will be included in the study. This will ensure that patients with early/mid-stage glaucoma will be homogeneously collected; avoids advanced glaucoma in which OBF may behave as a different disease state.
  • Best-corrected visual acuity will be of 0.5 or better with an ametropia <5D - Dioptric transparency, non smokers.
  • Age will be between 45 and 65 years.

Exclusion Criteria:n

  • Normal tension glaucoma, ocular hypertension, cardiovascular and/or metabolic diseases (known to affect blood flow, as diabetes and polycythemia)
  • Visual field defects other than glaucoma; use of vasoactive and/or anti-hypertensive drugs (systemic beta-blocker), use of acetazolamide
  • Hypersensibility and/or contraindications to any of the molecules studied
  • Previous ocular surgery
  • Pregnant or nursing women and use of one of drugs for erectile dysfunction
Both
45 Years to 65 Years
No
Contact: Teresa Rolle, MD 00390115666032 teresa.rolle@unito.it
Italy
 
NCT00796198
COS16102007
No
Rolle Teresa, MD,, University of Turin, Department of di Physiopathology Clinic-Section of Ophthalmology-Eye Clinic
University of Turin, Italy
Not Provided
Principal Investigator: Teresa Rolle, MD, Assistent Professor University of Turin, Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic
Principal Investigator: Teresa Rolle, MD, Assistent Professor University of Turin, Department of Clinical Physiopathology-Section of Ophthalmology-Eye Clinic
University of Turin, Italy
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP